Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Gross Margin (2020 - 2025)

BridgeBio Pharma's Gross Margin history spans 6 years, with the latest figure at 94.74% for Q4 2025.

  • For Q4 2025, Gross Margin rose 3017.0% year-over-year to 94.74%; the TTM value through Dec 2025 reached 95.82%, down 243.0%, while the annual FY2025 figure was 95.82%, 243.0% down from the prior year.
  • Gross Margin for Q4 2025 was 94.74% at BridgeBio Pharma, roughly flat from 94.56% in the prior quarter.
  • Across five years, Gross Margin topped out at 286.87% in Q4 2021 and bottomed at 63.5% in Q2 2023.
  • The 5-year median for Gross Margin is 89.97% (2023), against an average of 95.47%.
  • The largest annual shift saw Gross Margin tumbled -22147bps in 2022 before it soared 3537bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 286.87% in 2021, then plummeted by -77bps to 65.4% in 2022, then rose by 1bps to 65.73% in 2023, then decreased by -2bps to 64.57% in 2024, then surged by 47bps to 94.74% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Gross Margin are 94.74% (Q4 2025), 94.56% (Q3 2025), and 96.7% (Q2 2025).